Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Evopoint Biosciences
Evopoint BiosciencesChina - Beijing
1 program
1
Combination of Imipenem/Cilastatin and XNW4107Phase 31 trial
Active Trials
NCT05204563Completed450Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Evopoint BiosciencesCombination of Imipenem/Cilastatin and XNW4107

Clinical Trials (1)

Total enrollment: 450 patients across 1 trials

NCT05204563Evopoint BiosciencesCombination of Imipenem/Cilastatin and XNW4107

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

Start: Jul 2022Est. completion: Sep 2024450 patients
Phase 3Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space